Guillain-Barre syndrome
MONDO:0016218A spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients. GBS is clinically heterogeneous and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS) and some other regional variants.
Also known as: GBS, Guillain Barre syndrome, Guillain Barré syndrome, Guillain-Barre-Strohl syndrome, Guillain-Barré syndrome, Guillain-Barré-Strohl syndrome, post-infectious polyneuritis, post-infective polyneuritis
69 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
HPV vaccine shows promise for girls on Immune-Suppressing drugs
⭐️ VACCINE ⭐️ CompletedThis study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:36 UTC
-
New booster aims to shield the vulnerable from COVID-19
⭐️ VACCINE ⭐️ CompletedThis study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Research…
Phase: PHASE2, PHASE3 • Sponsor: Hipra Scientific, S.L.U • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:38 UTC
-
New drug VIS171 tested in humans for first time – could it tame autoimmune disease?
Disease control CompletedThis early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available ye…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug KINE-101 tested for Tough-to-Treat nerve disorder
Disease control CompletedThis early-stage trial tested a single dose of a new drug called KINE-101 in 9 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hadn't improved with steroids. The main goal was to check if the drug is safe and tolerable. Researchers also looked at whether…
Phase: PHASE1 • Sponsor: Kine Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could a drug speed recovery from Guillain-Barré syndrome?
Disease control CompletedThis Phase 3 trial tested the drug eculizumab in 57 people with severe Guillain-Barré syndrome (GBS), a rare nerve disorder that can cause paralysis. Participants received either eculizumab or a placebo once a week for four weeks, alongside standard treatment. The study measured …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:47 UTC
-
Blood filter shows promise for autoimmune patients
Disease control CompletedThis study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…
Phase: NA • Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Robot suit helps GBS patients take steps again
Symptom relief CompletedThis study tested whether the Atalante X exoskeleton, a robotic leg brace, is safe and helpful for people with Guillain-Barré syndrome who cannot walk. Eleven participants used the device in 20 training sessions over six weeks. Researchers measured safety, ease of use, and any im…
Phase: NA • Sponsor: Institut Guttmann • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Cutting salt and sugar may tame steroid side effects
Symptom relief CompletedThis study looked at whether a diet low in salt and sugar can reduce common side effects of corticosteroid treatment, such as weight gain, high blood pressure, and diabetes. Fifty adults with autoimmune diseases or asthma who were starting high-dose corticosteroids were randomly …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Scientists hunt for genetic and environmental triggers of rare muscle diseases
Knowledge-focused CompletedThis study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study reveals COVID-19 risks for autoimmune patients
Knowledge-focused CompletedThis study looked at over 13,000 people with chronic inflammatory rheumatism or autoimmune diseases who had or were suspected to have COVID-19. Researchers tracked how many developed severe COVID-19 requiring intensive care or leading to death. They also examined risk factors lik…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Rituximab infection risk under the microscope
Knowledge-focused CompletedThis completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New drug LAD191 tested for safety in autoimmune patients
Knowledge-focused CompletedThis early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather…
Phase: PHASE1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Scientists gather clues on mysterious immune defects
Knowledge-focused CompletedThis study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Robots teach brains to move again: new study tests smarter rehab
Knowledge-focused CompletedThis study tested whether robotic training that adjusts errors based on each person's abilities can improve motor learning in healthy adults and people with neurological conditions like stroke. Over 250 participants performed arm tasks with robotic devices while researchers measu…
Phase: NA • Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:12 UTC